Accelerated approval drug labels often lack information for clinical decision-making

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science
• Clinical Trial Design

Background:

• The US Food and Drug Administration (FDA) utilizes an accelerated approval pathway to expedite drug availability for serious conditions.
• This pathway often relies on surrogate markers as a proxy for clinical benefit, requiring post-approval studies for full approval.
• Ensuring clarity on drug labels is crucial for appropriate clinical use and decision-making.

Purpose of the Study:

• To evaluate the completeness of information on US FDA drug labels for medications approved via the accelerated approval pathway.
• To determine if labels adequately disclose the use of the accelerated approval pathway and the surrogate markers utilized.
• To assess whether labels describe post-approval commitment trial outcomes.

Main Methods:

• A retrospective, observational cohort study design was employed.
• Drug labels for accelerated approval indications were collected from Drugs@FDA and FDA Drug Label Repository.
• The study focused on drugs approved after January 1, 1992, and not fully approved by December 31, 2020.

Main Results:

• Out of 110 accelerated approval indications across 62 drugs lacking full approval, 13% of labels had insufficient information.
• Specifically, 7% of labels did not mention accelerated approval but described surrogate markers, while 4% mentioned neither.
• Notably, no labels described the clinical outcomes for required post-approval commitment trials.

Conclusions:

• Drug labels for indications granted accelerated approval require revision to include essential information as per FDA guidance.
• Improved label clarity is necessary to support informed clinical decision-making for patients and healthcare providers.
• The findings highlight a gap in communicating critical regulatory and clinical trial information on drug labels.